Utility Of Salivary CA-125 And LDH As Tumor Markers In Oral Malignancy
Abstract viewed = 170 times,
PDF downloaded = 89 times.
Article Sidebar
Published
Jul 31, 2018
Section
Original Research Articles
Main Article Content
Abstract
Background: The mortality and morbidity associated with oral squamous cell carcinoma(OSCC) can be greatly reduced if tumor markers which can detect OSCC at an early stage are available. This study attempts to use saliva as the diagnostic medium to determine the correlation of salivary CA 125 and LDH in tobacco users with and without potentially malignant disorders. Changes in CA 125 and LDH level can be used as a marker in patients with and without premalignant disease and can be used as a deterrent in continuation of the habit. Aims: To assess the role of CA 125 & LDH as a tumour marker in Oral cancer patients. Materials and methods: Cross sectional observational study .Time period: December 2015 to August 2017.Study area: OPD of tertiary care hospital in pune. Total participants: 150 persons. Under non-stimulatory conditions whole saliva sample was collected from each individual and was centrifuged. The resulting supernatant was used for estimation of CA 125 and LDH levels. Results: In present study, mean Salivary LDH level was found to be lowest among cases of healthy individuals while it was highest among individuals who were diagnosed and underwent treatment for malignancy. However there was insignificant difference seen between levels of diagnosed case of oral malignancy and the ones who underwent treatment for oral malignancy. Also mean Salivary CA-125 was lowest in healthy individuals and highest in individuals diagnosed with oral malignancy and the levels were seen to be reduced significantly in the one who underwent treatment for oral malignancies than those who didn’t. Conclusion: Salivary CA 125 and LDH has a role in early detection of oral malignancies and can be used as a diagnostic marker. However LDH levels are persistently raised even after treatment for oral malignancy.
Article Details
How to Cite
Yadav, S., JA, D., AR, S., & SS, C. (2018). Utility Of Salivary CA-125 And LDH As Tumor Markers In Oral Malignancy. International Journal of Clinical and Biomedical Research, 4(3), 65-69. https://doi.org/10.31878/ijcbr.2018.43.14
Copyright (c) 2018 Shweta rakesh Yadav, Deherkar JA, Sangle AR, Chandorkar SS
The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
The submitted papers are assumed to contain no proprietary material unprotected by patent or patent application; responsibility for technical content and for protection of proprietary material rests solely with the author(s) and their organizations and is not the responsibility of the journal. The main (first/corresponding) author is responsible for ensuring that the article has been seen and approved by all the other authors. It is the responsibility of the author to obtain all necessary copyright release permissions for the use of any copyrighted materials in the manuscript prior to the submission.
What are my rights as author?
It is important to check the policy for the journal to which you are submitting or publishing to establish your rights as
Author. Journal's standard policies allow the following re-use rights:
- The journal allow the author(s) to hold the copyright without restrictions.
- The journal allow the author(s) to obtain publishing rights without restrictions.
- You may do whatever you wish with the version of the article you submitted to the journal.
- Once the article has been accepted for publication, you may post the accepted version of the article on your own personal website, your department's website or the repository of your institution without any restrictions.
- You may not post the accepted version of the article in any repository other than those listed above (i.e. you may not deposit in the repository of another institution or a subject-matter repository) until 12 months after publication of the article in the journal.
- You may use the published article for your own teaching needs or to supply on an individual basis to research colleagues, provided that such supply is not for commercial purposes.
References
1. World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization; 2010;10(2):97.
2.Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM.GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. 2010 June:5-6.
3.Sparano A, Weinstein G, Chalian A, Yodul M, Weber R. Multivariate predictors of occult neck metastasis in early oral tongue cancer. Otolaryngol Head Neck Surg. 2004;131:472–6.
4.P.K Tsantoulis, N.G. Kastrinakis, A.D Tourvas, G. Laskaris, V.SGorgoulis. Advances in the biology of oral cancers. 2007;43:523-534.
5.Community Dent Oral Epidemiology, WHO guest editorial2005;33:397–399.
6.Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G, Gorgoulis VG. Advances in the biology of Oral cancer. 2007;43:523–34.
7.Elango JK, Gangadharan P, Sumithra S, Kuriakose MA. Trends of head and neck cancers in urban and rural India. Asian Pacific Journal of Cancer Prevention. 2006;7(1):108–112.
8.Sankaranarayanan R, Ramadas K, Thomas G, et al. Effect of screening on oral cancer mortality in Kerala, India: A cluster-randomised controlled trial. 2005;365(9475):1927–1933.
9.Allgar VL, Neal RD. Socio demographic factors and delays in the diagnosis of six cancers: Analysis of data from the ‘National Survey of NHS Patients: cancer‘ The British Journal of Cancer. 2005;92(11):1971–1975.
10.Diamandis EP. Tumour markers: Past, present, and future, Tumour markers: Physiology, pathobiology, technology, and clinicalapplications.2002:3–8.
11.Sokoll LJ, Chan DW. Clinical chemistry: Tumour markers. Clinical Oncology. 2004;3:1-2.
12.Marella S. Prognostic and predictive markers in early detection of different types of cancers for selected organ sites. 2013;8:5-42.
13.Ferlay J, Bray F, Pisani P, Parkin DM. GLOBACON 2000, cancer incidence, mortality and prevalence worldwide.2001;1:13-14.
14.Peacock S, Pogrel A, Schmidt BL. Exploring the reasons for delay intreatment of oral cancer. 2008;139:1346–52.
15.Gandolfo S, Pentenero M, Broccoletti R, Pagano M, Carrozzo M,Scully C. Toluidine blue uptake in potentially malignant oral lesions invivo: Clinical and histological assessment. 2006;42:89-95.
16.O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L: The CA 125 gene: an extracellular superstructure dominated by repeat sequences. 2001; 22:348–366.
17. Yin BW, Lloyd KO: Molecular cloning of the ca125 ovarian cancer antigen. identification as a new mucin 16. 2001;276:27371–27375.
18.Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. 2004;279:9190–9198.
19.. Hattrup CL, Gendler SJ: Structure and function of the cell surface (Tethered) Mucins. 2007;70:431–457.
20. Comamala M, Pinard M, Theriault C, Matte I, Albert A, Boivin M, et al. Down regulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH: OVCAR3 ovarian carcinoma cells. 2011;104:989–999.
21. Bast RC Jr, Spriggs DR. More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. 2011;121:429–430.
22. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. 2009;45:309–16.
23. Agrawal R, Chauhan A, Kumar P. Spectrum of Oral Lesions in A Tertiary Care Hospital. Journal of clinical and diagnostic research. 2015 Jun;9(6):EC11.
24. Pudasaini S, Barar R. Oral cavity lesions: A study of 21 cases. Journal of Pathology of Nepal. 2011;1:49–51.
25. Yellowitz JA, Horowitz AM, Drury TF, Goodman HS. Survey of U. S.Dentists knowledge and opinions about oral pharyngeal cancer.
2000;131:653–661.
26. Bagan J, Sarrion G, Jimenez Y. Oral cancer: clinical features. 2010;46:414–417.
27. Shpitzer T, Bahar G, Feinmesser R, Nagler RM. A comprehensive salivary analysis for oral cancer diagnosis. 2007;133:613–7.
28. Nagler RM, Lischinsky S, Diamond E, Klein I, Reznick AZ. New insights into salivary lactate dehydrogenase of human subjects.2001;137:363-9.
29.Joshi PS, Golgire S. A study of salivary lactate dehydrogenase isoenzyme levels in patients with oral leukoplakia and squamous cell carcinoma by gel electrophoresis method. Journal of oral and maxillofacial pathology. 2014 Sep;18(Suppl 1):S39.
30.Shpitzer T, Hamzany Y, Bahar G, Feinmesser R, Savulescu D, Borovoi I, et al. Salivary analysis of oral cancer biomarkers. 2009;101:1194–8.
31. Shetty SR, Chadha R, Babu S, Kumari S, Bhat S, Achalli S. Salivary lactate dehydrogenase levels in oral leukoplakia and oral squamous cell carcinoma: A biochemical and clinicopathological study. 2012;8:123–5.
32. Balan JJ, Rao RS, Premalatha BR, Patil S. Analysis of tumour marker CA 125 in saliva of normal and oral squamous cell carcinoma patients: a comparative study. 2012 Sep;13(5):671-5.
33. Geng XF, Du M, Han JX, Zhang M, Tang XF, Xing RD. Saliva CA125 and TPS levels in patients with oral squamous cell carcinoma. The International journal of biological markers. 2013;28(2):216-20.
34. Mohammed, Riham Abdelraouf Hyder. Salivary CA-125: A Tumour Marker for Oral Squamous Cell Carcinoma (Doctoral dissertation, University of Khartoum).2016 April;37:11Z.
2.Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM.GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. 2010 June:5-6.
3.Sparano A, Weinstein G, Chalian A, Yodul M, Weber R. Multivariate predictors of occult neck metastasis in early oral tongue cancer. Otolaryngol Head Neck Surg. 2004;131:472–6.
4.P.K Tsantoulis, N.G. Kastrinakis, A.D Tourvas, G. Laskaris, V.SGorgoulis. Advances in the biology of oral cancers. 2007;43:523-534.
5.Community Dent Oral Epidemiology, WHO guest editorial2005;33:397–399.
6.Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G, Gorgoulis VG. Advances in the biology of Oral cancer. 2007;43:523–34.
7.Elango JK, Gangadharan P, Sumithra S, Kuriakose MA. Trends of head and neck cancers in urban and rural India. Asian Pacific Journal of Cancer Prevention. 2006;7(1):108–112.
8.Sankaranarayanan R, Ramadas K, Thomas G, et al. Effect of screening on oral cancer mortality in Kerala, India: A cluster-randomised controlled trial. 2005;365(9475):1927–1933.
9.Allgar VL, Neal RD. Socio demographic factors and delays in the diagnosis of six cancers: Analysis of data from the ‘National Survey of NHS Patients: cancer‘ The British Journal of Cancer. 2005;92(11):1971–1975.
10.Diamandis EP. Tumour markers: Past, present, and future, Tumour markers: Physiology, pathobiology, technology, and clinicalapplications.2002:3–8.
11.Sokoll LJ, Chan DW. Clinical chemistry: Tumour markers. Clinical Oncology. 2004;3:1-2.
12.Marella S. Prognostic and predictive markers in early detection of different types of cancers for selected organ sites. 2013;8:5-42.
13.Ferlay J, Bray F, Pisani P, Parkin DM. GLOBACON 2000, cancer incidence, mortality and prevalence worldwide.2001;1:13-14.
14.Peacock S, Pogrel A, Schmidt BL. Exploring the reasons for delay intreatment of oral cancer. 2008;139:1346–52.
15.Gandolfo S, Pentenero M, Broccoletti R, Pagano M, Carrozzo M,Scully C. Toluidine blue uptake in potentially malignant oral lesions invivo: Clinical and histological assessment. 2006;42:89-95.
16.O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L: The CA 125 gene: an extracellular superstructure dominated by repeat sequences. 2001; 22:348–366.
17. Yin BW, Lloyd KO: Molecular cloning of the ca125 ovarian cancer antigen. identification as a new mucin 16. 2001;276:27371–27375.
18.Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. 2004;279:9190–9198.
19.. Hattrup CL, Gendler SJ: Structure and function of the cell surface (Tethered) Mucins. 2007;70:431–457.
20. Comamala M, Pinard M, Theriault C, Matte I, Albert A, Boivin M, et al. Down regulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH: OVCAR3 ovarian carcinoma cells. 2011;104:989–999.
21. Bast RC Jr, Spriggs DR. More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. 2011;121:429–430.
22. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. 2009;45:309–16.
23. Agrawal R, Chauhan A, Kumar P. Spectrum of Oral Lesions in A Tertiary Care Hospital. Journal of clinical and diagnostic research. 2015 Jun;9(6):EC11.
24. Pudasaini S, Barar R. Oral cavity lesions: A study of 21 cases. Journal of Pathology of Nepal. 2011;1:49–51.
25. Yellowitz JA, Horowitz AM, Drury TF, Goodman HS. Survey of U. S.Dentists knowledge and opinions about oral pharyngeal cancer.
2000;131:653–661.
26. Bagan J, Sarrion G, Jimenez Y. Oral cancer: clinical features. 2010;46:414–417.
27. Shpitzer T, Bahar G, Feinmesser R, Nagler RM. A comprehensive salivary analysis for oral cancer diagnosis. 2007;133:613–7.
28. Nagler RM, Lischinsky S, Diamond E, Klein I, Reznick AZ. New insights into salivary lactate dehydrogenase of human subjects.2001;137:363-9.
29.Joshi PS, Golgire S. A study of salivary lactate dehydrogenase isoenzyme levels in patients with oral leukoplakia and squamous cell carcinoma by gel electrophoresis method. Journal of oral and maxillofacial pathology. 2014 Sep;18(Suppl 1):S39.
30.Shpitzer T, Hamzany Y, Bahar G, Feinmesser R, Savulescu D, Borovoi I, et al. Salivary analysis of oral cancer biomarkers. 2009;101:1194–8.
31. Shetty SR, Chadha R, Babu S, Kumari S, Bhat S, Achalli S. Salivary lactate dehydrogenase levels in oral leukoplakia and oral squamous cell carcinoma: A biochemical and clinicopathological study. 2012;8:123–5.
32. Balan JJ, Rao RS, Premalatha BR, Patil S. Analysis of tumour marker CA 125 in saliva of normal and oral squamous cell carcinoma patients: a comparative study. 2012 Sep;13(5):671-5.
33. Geng XF, Du M, Han JX, Zhang M, Tang XF, Xing RD. Saliva CA125 and TPS levels in patients with oral squamous cell carcinoma. The International journal of biological markers. 2013;28(2):216-20.
34. Mohammed, Riham Abdelraouf Hyder. Salivary CA-125: A Tumour Marker for Oral Squamous Cell Carcinoma (Doctoral dissertation, University of Khartoum).2016 April;37:11Z.